Zymeworks Common Company Insiders
| ZYME Stock | USD 22.88 -0.35 -1.51% |
About 80 percent of all Zymeworks Common's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Zymeworks Common Stock suggests that quite a large number of insiders are very bullish. Zymeworks Common employs about 264 people. The company is managed by 34 executives with a total tenure of roughly 54 years, averaging almost 1.0 years of service per executive, having 7.76 employees per reported executive.
| Ali Tehrani CEO President, Chief Executive Officer, Co-Founder, Director |
| Neil Klompas President Chief Financial Officer, Executive Vice President - Business Operations |
Insider Sentiment
Aggressively Buying
Selling | Buying |
Latest Trades
| 2026-01-12 | Jeffrey T L Smith | Disposed 9310 @ 22.67 | View | ||
| 2026-01-05 | Paul Andrew Moore | Disposed 20110 @ 25.1 | View | ||
| 2025-12-22 | Kenneth Galbraith | Disposed 47528 @ 27.02 | View | ||
| 2025-05-19 | Ecor1 Capital, Llc | Acquired 5919 @ 11.78 | View | ||
| 2025-05-15 | Ecor1 Capital, Llc | Acquired 49502 @ 11.43 | View | ||
| 2025-04-16 | Ecor1 Capital, Llc | Acquired 73953 @ 11.16 | View | ||
| 2025-04-04 | Ecor1 Capital, Llc | Acquired 196438 @ 11.17 | View | ||
| 2025-04-02 | Ecor1 Capital, Llc | Acquired 74360 @ 11.85 | View | ||
| 2025-03-31 | Ecor1 Capital, Llc | Acquired 4397 @ 11.75 | View | ||
| 2025-03-26 | Ecor1 Capital, Llc | Acquired 43848 @ 12.24 | View | ||
| 2025-03-24 | Ecor1 Capital, Llc | Acquired 22689 @ 13.08 | View | ||
| 2025-03-21 | Ecor1 Capital, Llc | Acquired 31033 @ 12.78 | View | ||
| 2025-03-19 | Ecor1 Capital, Llc | Acquired 58306 @ 12.64 | View | ||
| 2025-03-17 | Ecor1 Capital, Llc | Acquired 56277 @ 12.23 | View | ||
| 2025-03-13 | Ecor1 Capital, Llc | Acquired 468356 @ 12.48 | View |
Following insider trading sentiment in Zymeworks Common can help investors add context around confidence, timing, and operating risk while the public narrative is still evolving. The signal is still regulated and disclosed under securities law, which is why the public filing record matters more than rumor or interpretation alone.
Zymeworks | Build AI portfolio with Zymeworks Stock |
Zymeworks Common Management Team Effectiveness
The company has return on total asset (ROA) of -14.29 % which implies that it generated a $14.29 loss per $100 of asset base. This is below the acceptable range for the industry. Similarly, it shows a return on stockholder's equity (ROE) of -26.72 %, which indicates that the return on shareholder capital is below zero.As of last week, Net Income Applicable To Common Shares is projected to grow to approximately 117.5 M, whereas Common Stock Shares Outstanding is moving lower toward about 49.1 M.
Stock Ownership Analysis
About 98.0% of the company outstanding shares are owned by institutional investors. The company recorded a loss per share of 1.08. Zymeworks Common Stock had not issued any dividends in recent years.Reviewing share-based compensation in Zymeworks Common Stock helps investors understand how management balances employee incentives against dilution risk. Shares outstanding are near 73.7 M. That is why investors should compare compensation intensity with revenue growth, margin progress, and free-cash-flow generation.
Zymeworks Common Quarterly Liabilities And Stockholders Equity | 346.53 Million |
Insider Trades History
Reviewing insider ownership in Zymeworks Common Stock helps investors understand how much of the equity base is controlled by people involved in running the business. Insiders currently hold about 1.20% of outstanding shares. Investors usually want to know whether that level supports alignment without creating excessive control risk. View all of Zymeworks Common's insider trades
Macro event markers
Stock Institutional Investors
Institutional ownership matters in Zymeworks Common Stock because pension funds, mutual funds, banks, and advisers can materially influence liquidity, governance, and price discovery. Used correctly, institutional data helps investors understand who may be setting the marginal price and how resilient that holder base could be under stress.
| Shares | Deutsche Bank Ag | 2025-09-30 | 1.5 M | Dimensional Fund Advisors, Inc. | 2025-12-31 | 1.2 M | Nextech Invest, Ltd. | 2025-12-31 | 1.1 M | Millennium Management Llc | 2025-09-30 | 1.1 M | Tang Capital Management Llc | 2025-09-30 | 1.1 M | State Street Corp | 2025-09-30 | 1.1 M | Capricorn Fund Managers Ltd | 2025-12-31 | 1 M | Vestal Point Capital Lp | 2025-12-31 | 865 K | Arrowstreet Capital Limited Partnership | 2025-12-31 | 700 K | Ecor1 Capital, Llc | 2025-12-31 | 23 M | Rubric Capital Management Lp | 2025-12-31 | 5.8 M |
Insider Trading Activities
Insider trading disclosures for Zymeworks Common Stock offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 1.73 Billion. Used properly, these records are better for context than for blind buy-or-sell signals.
Outstanding Bonds
Reviewing Zymeworks Common Stock bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. This is why bond analysis is not just a credit exercise; it also informs equity holders about solvency, optionality, and future capital-allocation pressure.
| US98981BAA08 Corp BondUS98981BAA08 | View | |
| US98980BAA17 Corp BondUS98980BAA17 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Corporate Filings
8K | 2nd of March 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 13th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of February 2026 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 2nd of February 2026 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F3 | 13th of January 2026 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 12th of January 2026 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 7th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 5th of January 2026 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Shares in Circulation | First Issued 2015-12-31 | Previous Quarter 75.8 M | Current Value 75.3 M | Average Shares Outstanding 48.9 M | Quarterly Volatility 21.4 M |
Macro event markers
Zymeworks Stock Holders Distribution
Institutional ownership analysis for Zymeworks Common Stock matters because banks, hedge funds, pension plans, and other professional investors can influence price and liquidity more forcefully than smaller holders. This matters because getting in early on a sponsorship cycle may help, but getting caught near a large-holder exit can have the opposite effect.
Zymeworks Common Market Cap and Value
Zymeworks Common Workforce Comparison
Zymeworks Common Stock holds the #5 position for number of employees relative to top peers. The total workforce of Health Care industry is at this time estimated at about 2,490. Zymeworks Common retains roughly 264 in number of employees claiming about 11% of equities under Health Care sector.
The company has Profit Margin (PM) of -77.0 %, which indicates that it's cost structure is outpacing its revenue. This is below the acceptable range for the industry. Similarly, it shows Operating Margin (OM) of -17.56 %, which suggests that for every $100 in revenue, $17.56 is lost before interest and taxes. Zymeworks Common Insider Trading History
Insider trading disclosures for Zymeworks Common Stock offer a structured way to watch how people closest to the business are behaving while expectations change across the market. Current market capitalization is about 1.73 Billion. Used properly, these records are better for context than for blind buy-or-sell signals.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2026-03-01 | 1.8333 | 33 | 18 | 1,390,559 | 428,905 |
| 2025-12-01 | 0.5 | 1 | 2 | 100,000 | 147,528 |
| 2025-06-01 | 4.5 | 9 | 2 | 5,710,840 | 5,086,562 |
| 2025-03-01 | 3.3 | 33 | 10 | 3,278,967 | 261,099 |
| 2024-09-01 | 1.0 | 1 | 1 | 360,000 | 0.00 |
| 2024-06-01 | 1.0 | 1 | 1 | 74,000 | 0.00 |
| 2024-03-01 | 1.0 | 12 | 12 | 1,029,332 | 303,029 |
| 2023-12-01 | 3.3333 | 10 | 3 | 5,421,071 | 2,436 |
| 2023-06-01 | 1.5 | 3 | 2 | 3,450,000 | 0.00 |
| 2023-03-01 | 4.0 | 12 | 3 | 2,882,108 | 8,185 |
| 2022-12-01 | 5.0 | 10 | 2 | 316,847 | 8,360 |
| 2022-03-01 | 2.5 | 10 | 4 | 833,853 | 23,329 |
| 2021-09-01 | 1.5 | 9 | 6 | 64,794 | 116,420 |
| 2021-06-01 | 1.0 | 8 | 8 | 65,266 | 146,341 |
| 2021-03-01 | 1.4375 | 23 | 16 | 444,680 | 76,349 |
| 2020-12-01 | 0.6875 | 11 | 16 | 77,920 | 132,270 |
| 2020-09-01 | 1.4 | 7 | 5 | 41,132 | 80,000 |
| 2020-06-01 | 10.0 | 10 | 1 | 64,575 | 1,000.00 |
| 2019-12-01 | 1.0 | 2 | 2 | 127,500 | 137,500 |
| 2019-06-01 | 1.0 | 8 | 8 | 65,884 | 44,992 |
| 2019-03-01 | 0.5333 | 8 | 15 | 515,913 | 694,425 |
Zymeworks Common Notable Stakeholders
Stakeholders matter for Zymeworks Common because not every influential participant is a shareholder acting with the same objective or time horizon. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Ali Tehrani | President, Chief Executive Officer, Co-Founder, Director | Profile | |
| Kenneth Galbraith | Chairman of the Board, President, Chief Executive Officer | Profile | |
| Christopher Astle | Chief Financial Officer, Senior Vice President | Profile | |
| Neil Klompas | Chief Financial Officer, Executive Vice President - Business Operations | Profile | |
| Leone MBA | EVP CFO | Profile | |
| Thomas Kreudenstein | Director Engineering | Profile | |
| Nina Weisser | Director Therapeutics | Profile | |
| Lota Zoth | Lead Independent Director | Profile | |
| Shrinal Inamdar | Director Relations | Profile | |
| Daniel JD | Corporate VP | Profile | |
| Jack Spinks | Associate Relations | Profile | |
| Neil MD | Chief Officer | Profile | |
| Mark Hollywood | Executive Operations | Profile | |
| Neil Josephson | Interim Chief Medical Officer | Profile | |
| Anthony Polverino | Executive Vice President - Early Development, Chief Scientific Officer | Profile | |
| Paul Moore | Chief Officer | Profile | |
| Diana Papove | Senior Communications | Profile | |
| Jeffrey MD | Executive Officer | Profile | |
| Diana Hausman | Chief Medical Officer | Profile | |
| Ryan Dercho | Senior Affairs | Profile | |
| Kenneth CA | CEO Chairman | Profile | |
| Sabeen MD | Senior Development | Profile | |
| Lindsey BSc | Vice Development | Profile | |
| Bijal MBA | Senior Finance | Profile | |
| Scott Platshon | Acting Officer | Profile | |
| Adam MBA | Acting Officer | Profile | |
| Diana BCom | Vice Communications | Profile | |
| Scott BSc | Acting Officer | Profile | |
| Barbara MBA | Senior Operations | Profile | |
| Victoria Spencer | Vice Tax | Profile | |
| Josemund MBBS | Managing Pacific | Profile | |
| Laura OConnor | Head Resources | Profile | |
| John Fann | Senior Sciences | Profile | |
| David Poon | VP Management | Profile |
Management Information & Data Sources
Zymeworks Common is a mid-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Management analysis is most useful when paired with profitability, leverage, and operating trend data. CEO is Kenneth Galbraith with 264 employees and 34 reported executives.
Data shown for Zymeworks Common Stock is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Analyst inputs may be included when coverage is available. Source publication cadence can introduce delays. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing Zymeworks Common Stock can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. A disciplined workforce review can reveal whether execution quality is improving beneath the top-line numbers.
Zymeworks Common Manpower Efficiency
Return on Zymeworks Common Manpower
| Revenue Per Employee | 401.4K | |
| Revenue Per Executive | 3.1M | |
| Net Loss Per Employee | 307.3K | |
| Net Loss Per Executive | 2.4M | |
| Working Capital Per Employee | 782K | |
| Working Capital Per Executive | 6.1M |
Popular Tools for Zymeworks Stock analysis
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |